ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.29
-1.18%
US Tech 100
20,867.60
-0.11%
S&P 500
5,994.57
-0.76%
US Dollar vs CAD
1.44879
0.46%
Bitcoin
98,962.18
-2.42%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Fortress Biotech Inc (FBIO)

  7. Fortress Biotech Inc (FBIO) News

FBIO

Fortress Biotech (FBIO)

Fortress Biotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FBIO
DateTimeSourceHeadlineSymbolCompany
01/27/20257:30AMGlobeNewswire Inc.Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCTNASDAQ:FBIOFortress Biotech Inc
01/23/20257:30AMGlobeNewswire Inc.Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNASDAQ:FBIOFortress Biotech Inc
01/14/20257:00AMGlobeNewswire Inc.Mustang Bio Announces Reverse Stock SplitNASDAQ:FBIOFortress Biotech Inc
01/06/20257:00AMGlobeNewswire Inc.Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes DiseaseNASDAQ:FBIOFortress Biotech Inc
01/06/20257:00AMPR Newswire (US)Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes DiseaseNASDAQ:FBIOFortress Biotech Inc
11/14/20243:10PMGlobeNewswire Inc.Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
11/14/20243:05PMGlobeNewswire Inc.Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
11/12/20243:01PMGlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
11/12/20247:30AMGlobeNewswire Inc.Mustang Bio Receives Positive Listing Determination from NasdaqNASDAQ:FBIOFortress Biotech Inc
11/07/20247:30AMGlobeNewswire Inc.Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaNASDAQ:FBIOFortress Biotech Inc
11/04/20246:00AMGlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaNASDAQ:FBIOFortress Biotech Inc
10/25/20247:30AMGlobeNewswire Inc.Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferenceNASDAQ:FBIOFortress Biotech Inc
10/24/20241:10PMGlobeNewswire Inc.Mustang Bio Announces Exercise of Warrants for $4 Million Gross ProceedsNASDAQ:FBIOFortress Biotech Inc
10/09/20247:30AMGlobeNewswire Inc.Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual SummitNASDAQ:FBIOFortress Biotech Inc
10/03/20247:30AMGlobeNewswire Inc.Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceNASDAQ:FBIOFortress Biotech Inc
09/26/20247:30AMGlobeNewswire Inc.Fortress Biotech to Participate in October 2024 Investor ConferencesNASDAQ:FBIOFortress Biotech Inc
09/20/20247:30AMGlobeNewswire Inc.Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private PlacementsNASDAQ:FBIOFortress Biotech Inc
09/09/20247:30AMGlobeNewswire Inc.Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) ConferenceNASDAQ:FBIOFortress Biotech Inc
09/04/20247:30AMGlobeNewswire Inc.Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:FBIOFortress Biotech Inc
09/04/20247:15AMGlobeNewswire Inc.Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:FBIOFortress Biotech Inc
09/03/20247:30AMGlobeNewswire Inc.Avenue Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:FBIOFortress Biotech Inc
08/13/20243:05PMGlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
08/12/20243:01PMGlobeNewswire Inc.Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
08/09/20243:05PMGlobeNewswire Inc.Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
08/06/20243:01PMGlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024NASDAQ:FBIOFortress Biotech Inc
07/25/20247:30AMGlobeNewswire Inc.Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027NASDAQ:FBIOFortress Biotech Inc
07/11/20243:05PMGlobeNewswire Inc.Journey Medical Corporation Appoints Michael C. Pearce to Board of DirectorsNASDAQ:FBIOFortress Biotech Inc
07/05/20243:05PMGlobeNewswire Inc.Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockNASDAQ:FBIOFortress Biotech Inc
06/21/20243:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:FBIOFortress Biotech Inc
06/20/20247:30AMGlobeNewswire Inc.Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:FBIOFortress Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:FBIO

Your Recent History

USOTC
MGON
Megola (PK)
NASDAQ
SMCI
Super Micro Computer
USOTC
AFFU
Affluence (PK)
USOTC
LQMT
Liquidmetal Technologies (QB)
COIN
XRPUSD
Ripple
USOTC
IQST
iQSTEL (QX)
USOTC
RITE
MineralRite (PK)
USOTC
HMBL
HUMBL (PK)
USOTC
RDGL
Vivos (QB)
USOTC
TPTW
TPT Global Tech (CE)
NASDAQ
NB
NioCorp Developments
NASDAQ
TSLA
Tesla
NASDAQ
TNXP
Tonix Pharmaceuticals
USOTC
AABB
Asia Broadband (PK)
USOTC
BIEL
Bioelectronics (PK)
USOTC
RNVA
Rennova Health (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads